Skip to main content

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Phase 2/3 Adaptive Study of VX-147 in Adults and Adolescents With APOL1- Mediated Proteinuric Kidney Disease

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Phase 2/3 Adaptive Study of VX-147 in Adults and Adolescents With APOL1- Mediated Proteinuric Kidney Disease

Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 34
  • Page 35
  • Page 36
  • Page 37
  • Page 38
  • Page 39
  • Page 40
  • Page 41
  • Page 42
  • …
  • Next page Next
  • Last page Last
Subscribe to